File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s00535-015-1128-2
- Scopus: eid_2-s2.0-84944596600
- PMID: 26446756
- WOS: WOS:000374669500008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability
Title | Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability |
---|---|
Authors | |
Keywords | Hepatitis B virus Hepatitis B surface antigen Antibody to hepatitis B surface antigen Covalently closed circular DNA Antiviral |
Issue Date | 2016 |
Publisher | Springer Japan. The Journal's web site is located at http://link.springer-ny.com/link/service/journals/00535/index.htm |
Citation | Journal of Gastroenterology, 2016, v. 51 n. 5, p. 487-495 How to Cite? |
Abstract | Background:
Hepatitis B surface antigen (HBsAg) seroclearance is the recommended treatment end point for nucleoside analogue (NA) therapy in chronic hepatitis B, yet the underlying kinetics and durability of HBsAg seroclearance in NA-treated patients have not been well described.
Methods:
We compared the HBsAg kinetics and long-term serologic outcomes of 51 chronic hepatitis B patients achieving HBsAg seroclearance during NA therapy with those of 51 HBsAg-positive controls, matched for age, sex, hepatitis B e antigen status, NA type, and treatment duration. Viral profiles before and after HBsAg seroclearance during and after NA treatment cessation were determined.
Results:
The median time to HBsAg seroclearance and the median follow-up duration after HBsAg seroclearance were 61.2 and 51.6 months respectively. Patients achieving HBsAg seroclearance maintained high median rates of HBsAg reduction throughout therapy (first 6 months, 0.40 IU/mL/year; after year 1, 0.39 IU/mL/year; p = 0.809). For controls, the median rate of HBsAg reduction was significantly slower with time (first 6 months and after year 1, 0.19 and 0.05 IU/mL/year; p = 0.006). The difference in the median HBsAg reduction rates after year 1 between the two groups was significant (p < 0.001). The cumulative rates of antibody to HBsAg development and HBsAg seroreversion 72 months after HBsAg seroclearance were 68.9 and 8.3 % (one patient receiving immunosuppressive therapy; one patient with pre-S/S variant), respectively. Among 22 patients who discontinued therapy after HBsAg seroclearance, 21 remained HBsAg negative with undetectable hepatitis B virus DNA and one patient with reactivation had the pre-S/S variant.
Conclusion:
NA-treated patients achieving HBsAg seroclearance uniquely maintained high rates of HBsAg reduction throughout treatment, with HBsAg seroclearance durable in most of the patients after treatment cessation. |
Persistent Identifier | http://hdl.handle.net/10722/226362 |
ISSN | 2023 Impact Factor: 6.9 2023 SCImago Journal Rankings: 2.099 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Huang, FY | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Liu, SHK | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2016-06-17T07:43:38Z | - |
dc.date.available | 2016-06-17T07:43:38Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Journal of Gastroenterology, 2016, v. 51 n. 5, p. 487-495 | - |
dc.identifier.issn | 0944-1174 | - |
dc.identifier.uri | http://hdl.handle.net/10722/226362 | - |
dc.description.abstract | Background: Hepatitis B surface antigen (HBsAg) seroclearance is the recommended treatment end point for nucleoside analogue (NA) therapy in chronic hepatitis B, yet the underlying kinetics and durability of HBsAg seroclearance in NA-treated patients have not been well described. Methods: We compared the HBsAg kinetics and long-term serologic outcomes of 51 chronic hepatitis B patients achieving HBsAg seroclearance during NA therapy with those of 51 HBsAg-positive controls, matched for age, sex, hepatitis B e antigen status, NA type, and treatment duration. Viral profiles before and after HBsAg seroclearance during and after NA treatment cessation were determined. Results: The median time to HBsAg seroclearance and the median follow-up duration after HBsAg seroclearance were 61.2 and 51.6 months respectively. Patients achieving HBsAg seroclearance maintained high median rates of HBsAg reduction throughout therapy (first 6 months, 0.40 IU/mL/year; after year 1, 0.39 IU/mL/year; p = 0.809). For controls, the median rate of HBsAg reduction was significantly slower with time (first 6 months and after year 1, 0.19 and 0.05 IU/mL/year; p = 0.006). The difference in the median HBsAg reduction rates after year 1 between the two groups was significant (p < 0.001). The cumulative rates of antibody to HBsAg development and HBsAg seroreversion 72 months after HBsAg seroclearance were 68.9 and 8.3 % (one patient receiving immunosuppressive therapy; one patient with pre-S/S variant), respectively. Among 22 patients who discontinued therapy after HBsAg seroclearance, 21 remained HBsAg negative with undetectable hepatitis B virus DNA and one patient with reactivation had the pre-S/S variant. Conclusion: NA-treated patients achieving HBsAg seroclearance uniquely maintained high rates of HBsAg reduction throughout treatment, with HBsAg seroclearance durable in most of the patients after treatment cessation. | - |
dc.language | eng | - |
dc.publisher | Springer Japan. The Journal's web site is located at http://link.springer-ny.com/link/service/journals/00535/index.htm | - |
dc.relation.ispartof | Journal of Gastroenterology | - |
dc.subject | Hepatitis B virus | - |
dc.subject | Hepatitis B surface antigen | - |
dc.subject | Antibody to hepatitis B surface antigen | - |
dc.subject | Covalently closed circular DNA | - |
dc.subject | Antiviral | - |
dc.title | Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability | - |
dc.type | Article | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Huang, FY: fungyu@hkucc.hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Liu, SHK: drkliu@hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Cheung, KSM=rp02532 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/s00535-015-1128-2 | - |
dc.identifier.pmid | 26446756 | - |
dc.identifier.scopus | eid_2-s2.0-84944596600 | - |
dc.identifier.hkuros | 258639 | - |
dc.identifier.volume | 51 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 487 | - |
dc.identifier.epage | 495 | - |
dc.identifier.isi | WOS:000374669500008 | - |
dc.publisher.place | Japan | - |
dc.identifier.issnl | 0944-1174 | - |